Cart
sales@molnova.com
Fosravuconazole L-lysine ethanolate
CAS No. 914361-45-8
Fosravuconazole L-lysine ethanolate( BMS-379224 L-lysine ethanolate | E-1224 L-lysine ethanolate )
Catalog No. M24954 CAS No. 914361-45-8
FosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 30 | In Stock |
|
| 5MG | 44 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 211 | In Stock |
|
| 100MG | 347 | In Stock |
|
| 200MG | 490 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFosravuconazole L-lysine ethanolate
-
NoteResearch use only, not for human use.
-
Brief DescriptionFosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.
-
DescriptionFosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.(In Vitro):Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species.(In Vivo):Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain.
-
In VitroFosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species.
-
In VivoFosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain. Animal Model:Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain).Dosage:10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg Administration:Oral administration; daily; for 20 days Result:Suppressed the parasitemia and prevented death.
-
SynonymsBMS-379224 L-lysine ethanolate | E-1224 L-lysine ethanolate
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number914361-45-8
-
Formula Weight739.7
-
Molecular FormulaC31H40F2N7O8PS
-
Purity>98% (HPLC)
-
SolubilityDMSO:48mg/mL (64.89mM)
-
SMILESN#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Palmitoyl Tetrapepti...
Palmitoyl Tetrapeptide-3 (Rigin) is a synthetic peptide, corrspending to 341-344 amino acid sequence of IgG human H-chain, with phagocytosis stimulating activity.Palmitoyl Tetrapeptide-3 stimulates expression of GCP-2 (Granulocyte Chemotactic Protein), which is a chemotactic protein that can recruit cells involved in the preparation and cleansing of the site, to damaged areas.
-
[Pro3]-GIP (Mouse)
GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.
-
Hederoside D2
Cauloside C is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside C exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines.
